XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | nl | no | nz | pt | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

ValueSets, Authority Hl7

17,520 resources

By Version

R2: 0
R2B: 0
R3: 618
R4: 13,316
R4B: 216
R5: 3,341
R6: 29

By Realm

none: 782
au: 53
be: 108
ca: 49
ch: 390
cl: 148
cr: 11
cz: 46
de: 50
dk: 16
ee: 55
eu: 306
fi: 4
fr: 38
it: 92
nl: 402
no: 6
nz: 17
pt: 11
se: 10
us: 10,860
uv: 4,001
vn: 23
other: 5

Start Prev Rows 1400 - 1600 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Source(s)
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.176	Office and Wellness Visits for General Screening	active	2024-08	us	cms
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.177	Office and Wellness Visits for General Screening	active	2024-08	us	cpt
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.178	Office and Wellness Visits for General Screening	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.28	Non Acute Encounter Codes CPT	active	2024-06	us	cpt
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.29	Non Acute Encounter Codes HCPCS	active	2024-06	us	cms
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.31	Bleeding Event Diagnosis Codes ICD9	active	2024-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.78	Statin Associated Muscle Symptoms	active	2021-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.84	Statin Associated Muscle Symptoms	active	2024-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.85	Statin Associated Muscle Symptoms	active	2024-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1108.99	Underweight	active	2022-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.11	Cornual Ectopic Pregnancy	active	2021-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.12	Cornual Ectopic Pregnancy	active	2021-06	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.13	Perforation of Uterus	active	2021-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.14	Perforation of Uterus	active	2021-06	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.15	Uterine Rupture	active	2021-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.16	Uterine Rupture	active	2021-06	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.17	Transabdominal Cerclage	active	2021-06	us	cms
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.18	Transabdominal Cerclage	active	2022-03	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.2	Transabdominal Cerclage	active	2021-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.21	Intravenous or Intraarterial Thrombolytic tPA Therapy Prior to Arrival	active	2021-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.23	Intensive Care Unit	active	2021-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.24	Uterine Horn	active	2021-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.25	Metroplasty	active	2021-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.3	Medical Induction of Labor	active	2021-06	us	cms
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.35	Placenta Previa	active	2021-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.36	Placenta Accreta Spectrum Previa or Vasa Previa	active	2024-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.37	Placenta Accreta Spectrum Previa or Vasa Previa	active	2023-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.38	Outpatient Surgery Service	active	2019-04	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.41	Statin Allergen	active	2022-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.42	Statin Allergen	active	2021-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.50	Rivaroxaban for VTE Prophylaxis	active	2022-02	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.51	Prasugrel	active	2021-02	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.52	Pharmacological Contraindications For Antithrombotic Therapy	active	2022-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.53	Acute Renal Failure	active	2024-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.54	Total Parenteral Nutrition	active	2021-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.55	Intravenous Thrombolytic tPA Therapy	active	2021-02	us	cms
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.56	Intraarterial Thrombolytic tPA Therapy	active	2021-02	us	cms
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.57	Ischemic Stroke Thrombosis	active	2021-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.58	Ischemic Stroke Thrombosis	active	2021-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.59	Ischemic Stroke Other	active	2021-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.60	Ischemic Stroke Other	active	2021-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.61	Antithrombotic Therapy Antiplatelet	active	2025-02	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.62	Antithrombotic Therapy for Ischemic Stroke	active	2021-04	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.63	Present On Admission is Yes or Exempt	active	2022-01	us	cms
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.64	Application of Venous Foot Pumps	active	2022-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.65	Application of Intermittent Pneumatic Compression Devices	active	2022-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.66	Application of Graduated Compression Stockings	active	2022-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.67	20 to 42 Plus Weeks Gestation	active	2023-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.68	37 to 42 Plus Weeks Gestation	active	2023-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.69	37 to 38 Weeks Gestation	active	2023-03	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.70	20 to 42 Plus Weeks Gestation	active	2023-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.71	20 to 42 Plus Weeks Gestation	active	2025-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.72	37 to 42 Plus Weeks Gestation	active	2023-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.73	37 to 42 Plus Weeks Gestation	active	2023-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.74	37 to 38 Weeks Gestation	active	2023-03	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.75	37 to 38 Weeks Gestation	active	2023-03	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.76	History of Atrial Ablation	active	2022-11	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.77	Placenta Accreta Spectrum Previa or Vasa Previa	active	2024-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1110.78	Placenta Previa	active	2023-11	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.143	Observation Services	active	2021-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.159	All Primary and Secondary Cancer	active	2023-03	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.161	All Primary and Secondary Cancer	active	2022-03	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.163	Emergency Department Evaluation	active	2020-03	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.164	Admit Inpatient	active	2021-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.171	Opioid Use Disorder	active	2024-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.173	Sickle Cell Disease with and without Crisis SNOMED	active	2024-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.174	Sickle Cell Disease with and without Crisis ICD	active	2024-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.175	Sickle Cell Disease with and without Crisis	active	2024-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.176	Opioid Medication Assisted Treatment (MAT) HCPCS	active	2024-02	us	cpt
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.177	Opioid Medication Assisted Treatment (MAT)	active	2025-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.178	Cancer Related Pain ICD 10	active	2024-02	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.179	Cancer Related Pain SNOMED	active	2024-02	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1111.180	Cancer Related Pain	active	2024-02	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.10	Care Experience Preferences at End of Life LOINC	active	2024-02	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.12	Healthcare Agent Ordinality	active	2020-12	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.14	ADIClauseTypeVS	active	2022-08	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.17	Preconditions for Treatment Preferences	active	2024-03	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.22	Advance Directive Document Types	active	2024-07	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.23	AD Conditions and Prognosis Scenarios	active	2023-08	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.26	Healthcare Agent or Advisor Indicator	active	2024-03	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.27	Initial Treatment portable medical order options	active	2024-08	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.28	Cardiopulmonary Resuscitation Order Options	active	2024-09	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.30	Cardiopulmonary Resuscitation Order Procedures	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.31	Cardiopulmonary Resuscitation Procedures Grouping	active	2024-09	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.32	Additional Portable Medical Order Procedures	active	2025-04	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.33	Initial Treatment Portable Medical Order Procedures Grouping	active	2024-09	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.34	Additional portable medical order Procedures Grouping	active	2024-09	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.35	Medically Assisted Nutrition Order Options	active	2024-09	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.36	Medically Assisted Nutrition Portable Medical Order Procedures Grouping	active	2024-09	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.37	Healthcare Agent Powers	active	2024-11	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.38	Personal Health Goal Options LOINC	active	2025-03	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.40	Portable Medical Order Document Types	active	2025-04	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.41	Advance Healthcare Directive Document Types Grouper	active	2025-04	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1115.8	Treatment Intervention Preferences at End of Life LOINC	active	2025-04	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.1	Rituximab Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.100	Pathological M Stage M1c	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.101	Pathological N Stage N3	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.102	N Stage pN1a	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.103	N Stage pN1b	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.105	Pathological N Stage pN1mi	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.106	Pathological N Stage N2b	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.107	Pathological N Stage N2a	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.108	Pathological N Stage N2	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.109	Pathological N Stage N1b	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.110	Pathological N Stage N1a	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.112	Pathological N Stage N0	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.114	Pathological T Stage T4d	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.115	Pathological T Stage T4c	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.116	Pathological T Stage T4b	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.117	Pathological T Stage T4a	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.118	Pathological T Stage T4	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.120	N Stage N2C	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.121	T Stage T3c	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.122	T Stage T3b	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.123	T Stage T3a	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.124	Pathological T Stage T3	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.125	T Stage T2c	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.126	T Stage T2b	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.127	T Stage T2a	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.128	Pathological T Stage T2	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.129	Pathological T Stage T1c	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.132	Pathological T Stage T1b	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.135	Pathological T Stage T1a	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.136	Pathological T Stage T1	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.137	Pathological T Stage T1mic	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.139	Pathological T Stage T0	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.142	Cancer Stage III	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.143	Cancer Stage IIIA	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.144	Cancer Stage IIIB	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.145	Cancer Stage IIIC	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.146	Cancer Stage IV	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.147	Cancer Stage IVA	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.148	Cancer Stage IVB	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.149	Cancer Stage IVC	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.151	Cisplatin Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.153	Vinorelbine Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.154	Gemcitabine Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.155	Docetaxel	active	2024-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.156	Pemetrexed Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.158	Vinblastine Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.160	ECOG Performance Status	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.161	ECOG Performance Status	active	2020-10	us	loinc
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.162	ECOG Performance Status	active	2022-03	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.164	Karnofsky Performance Status	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.165	Carboplatin Injectable	active	2020-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.166	Paclitaxel	active	2024-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.168	Doxorubicin Injectable	active	2022-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.169	Irinotecan Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.179	Bevacizumab Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.181	Methotrexate	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.184	Breast Cancer	active	2022-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.185	Breast Cancer	active	2023-07	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.191	Cancer Stage II	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.192	Cancer Stage IIA	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.193	Cancer Stage IIB	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.194	Pertuzumab Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.196	Ixabepilone Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.197	Goserelin	active	2024-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.200	Epirubicin Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.202	Ramucirumab Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.204	Letrozole	active	2024-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.206	Exemestane	active	2024-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.209	Fluorouracil	active	2024-09	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.210	Capecitabine Oral	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.222	Aprepitant Oral	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.223	Fosaprepitant Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.255	Colorectal Cancer	active	2021-12	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.256	Colorectal Cancer	active	2021-12	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.257	Colorectal Cancer Chemotherapy	active	2023-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.280	Cancer Stage IA	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.281	Cancer Stage IB	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.286	Cancer Stage IIC	active	2024-07	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.291	Positive Result	active	2024-12	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.292	Negative Result	active	2015-12	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.300	Pathological N Stage N1C	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.332	Daunorubicin Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.336	Palonosetron Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.341	External Beam Radiotherapy	active	2024-04	us	cpt
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.349	Metastatic Cancer	active	2023-12	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.439	T Category	active	2018-05	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.440	N Category	active	2018-05	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.441	M Category	active	2018-05	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.442	TNM Stage Group	active	2018-05	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.449	Opioids	active	2024-03	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.492	Pharmacological interventions for depression	active	2024-05	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.535	Ovarian Cancer	active	2023-05	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.536	Ovarian Cancer	active	2023-07	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.537	Fallopian Tube Cancer	active	2022-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.539	Fallopian Tube Cancer	active	2022-06	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.541	Peritoneal Cancer	active	2022-06	us	icd
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.542	Peritoneal Cancer	active	2023-07	us	vsac
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.547	Cancer Stage 1C	active	2024-12	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.555	Gender Female	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.556	Gender Male	active	2024-06	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.557	Pathological N Stage N3a	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.558	Pathological N Stage N3b	active	2024-08	us	sct
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.560	Rolapitant Oral	active	2024-07	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.599	Obinutuzumab Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.600	Ofatumumab Injectable	active	2024-12	us	rx
us.nlm.vsac	R4	2.16.840.1.113762.1.4.1116.602	Neurokinin 1 Receptor Antagonist	active	2024-07	us	vsac